Dr. Jason Fung Asks the Question Nobody Wants to Hear
What if the obesity crisis is not really about willpower, and it is not really about medication either? Dr. Jason Fung, a nephrologist who became one of the most prominent voices in the fasting world, sits down with the CrossFit Podcast to make a case that most people are looking at weight loss from the wrong angle entirely.
Fung is the author of The Obesity Code, which reframed obesity as a hormonal problem rather than a caloric one. In this conversation, he takes on Ozempic, fasting, food addiction, and the food industry with his usual directness. Whether you agree with all of his positions or not, he raises questions that deserve honest answers.
Ozempic: Tool or Crutch?
Fung is not anti-Ozempic. He acknowledges that semaglutide works. People lose weight on it. The GLP-1 mechanism is real, and the clinical data is strong. But he asks a question that the pharma marketing machine would rather you not think about: what happens when you stop taking it?
The data on weight regain after stopping GLP-1 medications is not great. Most people regain a significant portion of the weight within a year of discontinuation. Fung argues that this points to a fundamental problem with the approach. If the drug works by suppressing appetite but does nothing to address why your appetite is dysregulated in the first place, you have not fixed anything. You have just managed a symptom.
This is not a popular take in a world where Ozempic prescriptions are skyrocketing, but it is a legitimate clinical concern.
Fasting as the Original GLP-1 Hack
Here is where Fung's argument gets interesting. Fasting naturally increases your body's own GLP-1 production. When you fast, your gut releases GLP-1 as part of the feedback loop that regulates hunger and satiety. So in a sense, fasting does some of what Ozempic does, just through your body's own machinery rather than an injected pharmaceutical.
Fung is careful not to claim that fasting is a perfect substitute for semaglutide. The magnitude of appetite suppression from a weekly Ozempic injection is probably greater than what you get from intermittent fasting alone. But he argues that fasting addresses the root cause in ways that medication cannot, by resetting insulin sensitivity, improving metabolic flexibility, and giving your digestive system regular breaks.
Food Addiction Is Real, and the Food Industry Knows It
The middle portion of this conversation digs into food addiction, and Fung does not pull punches. Ultra-processed foods are engineered to override your satiety signals. The combination of sugar, fat, and salt in specific ratios triggers dopamine responses that mirror addictive substances. This is not conspiracy theory. The food science literature documents this clearly.
Fung connects this to the obesity epidemic in a way that reframes the entire conversation. If people are eating processed food that is literally designed to make them eat more, blaming them for lacking discipline is like blaming an alcoholic for being around an open bar 24 hours a day. The environment is the problem, and no amount of medication fully addresses a toxic food environment.
Three Types of Hunger: The New Framework
Fung previews ideas from his upcoming book, The Hunger Code, which proposes that there are three distinct types of hunger. This framework changes how you think about appetite and eating behavior. Not all hunger signals are the same, and treating them the same way, whether through fasting, medication, or diet, misses important distinctions.
He does not go into full detail (that is what the book is for), but the general idea is that hormonal hunger, hedonic hunger (pleasure-driven eating), and habitual hunger each have different drivers and require different strategies. GLP-1 drugs primarily address hormonal hunger. They are less effective against the hedonic and habitual types. Fasting, behavioral change, and food environment modification may be better tools for those.
The Complementary Approach
The most practical takeaway from this conversation is not that you should choose fasting over Ozempic. It is that the two are not mutually exclusive, and both are incomplete without addressing food quality. Fung describes patients who use semaglutide as a bridge while establishing fasting habits and cleaning up their diet, with the goal of eventually tapering off the medication.
This is a mature, nuanced position that you rarely hear from either side of the debate. The pro-Ozempic camp sometimes acts like the drug is all you need. The anti-medication camp acts like fasting solves everything. Fung is saying: use the tools that work, understand their limitations, and build habits that make the tools unnecessary over time.
The Clinical Data on Weight Regain After GLP-1 Discontinuation
Fung mentions weight regain as a concern, and the numbers back him up. The STEP 1 extension trial found that participants who stopped semaglutide regained about two-thirds of their lost weight within a year. A separate study in the New England Journal of Medicine showed similar patterns with tirzepatide, with participants regaining roughly half their weight loss by 52 weeks post-discontinuation.
These are averages, and individual results vary widely. Some people maintain most of their loss, particularly those who made significant dietary and exercise changes during treatment. Others regain all of it and then some. The data strongly suggests that GLP-1 drugs without concurrent lifestyle changes produce temporary results for most users. This is the core of Fung's argument, and on this point, the evidence is on his side.
How This Video Compares to Other GLP-1 Content in the FormBlends Library
Fung's perspective is the most lifestyle-focused take in the FormBlends video collection. If you compare it to Johann Hari's interview ("They're Lying to You About the Side Effects of Ozempic"), Hari catalogs specific medical risks while Fung questions the entire treatment model. The two are complementary rather than contradictory. Hari says "here are the dangers." Fung says "here is why the approach itself may be incomplete."
For a view from the other direction, Dr. Spencer Nadolsky's video on GLP-1 drugs vs. bariatric surgery ("GLP-1s or Weight Loss Surgery: Obesity Doctors Reveal the Truth") represents the conventional obesity medicine perspective. Nadolsky is more comfortable with long-term medication use and frames GLP-1 drugs as a chronic disease treatment rather than a temporary intervention. Watching Fung and Nadolsky back-to-back gives you the full spectrum of informed medical opinion on these drugs.
Questions to Ask Your Doctor If Fung's Ideas Resonate
If you are interested in combining fasting with GLP-1 therapy, or if you want to explore fasting as an eventual off-ramp from medication, bring these specific questions to your next appointment.
Ask whether your current health status makes fasting safe. People with type 1 diabetes, a history of eating disorders, active gallbladder disease, or who are pregnant should not fast without close medical supervision, and in some cases should not fast at all.
Ask about monitoring. If you start intermittent fasting while on semaglutide, your blood sugar, electrolytes, and hydration status may change. Your doctor may want to check labs more frequently during the transition.
Ask about medication timing. Some GLP-1 users find that injection day is the wrong day to fast because nausea peaks in the first 24-48 hours after injection. Scheduling your fasting window on non-injection days can make the experience much more tolerable.
Ask about a tapering timeline. If your goal is to eventually use fasting and dietary changes to replace GLP-1 medication, your doctor can help you create a gradual dose reduction plan with clear metrics for success at each step. Stopping cold turkey without a plan is the fastest path to full regain.
Finally, ask about tracking your body's own GLP-1 response. Fasting blood work including insulin, glucose, and GLP-1 levels at baseline and after a few months of combined therapy can show whether your endogenous hormone production is improving. That data gives you and your doctor objective evidence to guide the tapering decision rather than guessing.
What the Video Does Not Cover
Fung's perspective is shaped by his background in nephrology and metabolic medicine, but he does not address several practical questions that listeners will have. He does not discuss specific fasting protocols in detail here. If you want to start intermittent fasting while on a GLP-1, the timing around your injection day matters, and this conversation does not get into that. He also does not talk about the risks of fasting for people with certain conditions like type 1 diabetes, eating disorder history, or pregnancy. And while his three-hunger framework is interesting, it is still a preview of unreleased work, so the full evidence and methodology behind it are not available to evaluate yet.
Why This Matters for You
If you are on a GLP-1 medication, considering one, or trying to lose weight through other means, this conversation gives you a broader framework than most. Fung is not trying to sell you a fasting program. He is trying to get you to think about obesity as a systemic problem with systemic solutions, not a single-drug fix.
A Practical Starting Point
If Fung's argument resonates and you want to explore fasting alongside your GLP-1 medication, start with a simple 16:8 intermittent fasting window and talk to your prescriber first. Track how it affects your hunger patterns, energy levels, and side effects from the medication. Many patients find that a consistent eating window reduces GLP-1 nausea because meals become more predictable and portion sizes more consistent. The goal is not to white-knuckle through hunger. It is to rebuild a relationship with food signals that decades of processed eating may have disrupted.